GV has contributed to a $92m series B for Tenaya, three years after it was spun out of Gladstone Institutes and University of Texas Southwestern Medical Center.
Tenaya Therapeutics, a US-based developer of treatments for heart disease based on research at Gladstone Institutes and University of Texas Southwestern Medical Center, yesterday raised $92m in a series B round led by Casdin Capital.
GV, an early-stage corporate venturing subsidiary of technology conglomerate Alphabet, also took part in the round, as did Column Group and a range of undisclosed new and existing shareholders.
Founded in 2016, Tenaya is working on drugs that address the underlying causes of…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
